Merck & Co. (MRK)
(Delayed Data from NYSE)
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth A Momentum B VGM
Zacks News
The Story of the Greatest Mom and Pop Investor Ever
by Tracey Ryniec
Anne Scheiber grew $5,000 into $22 million over 50 years. How'd she do it?
Merck (MRK) Enters Into Circular RNA Collaboration With Orna
by Zacks Equity Research
Merck (MRK) is set to make an upfront payment of $150 million to Orna for rights to the latter's circular RNA technology to make vaccines and therapeutics for infectious disease and oncology.
Quest Diagnostics' (DGX) Base Volume Revives, New Ruling Aids
by Zacks Equity Research
With a bullish expectation for the remainder of 2022, Quest Diagnostics (DGX) raises its full-year guidance.
Here's Why You Should Retain Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) better-than-expected results and robust international performance.
AstraZeneca's (AZN) Lynparza sNDA Gets FDA Priority Tag
by Zacks Equity Research
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.
Is Invesco Dow Jones Industrial Average Dividend ETF (DJD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DJD
Illumina (ILMN) Q2 Earnings Miss Estimates, Slashes '22 View
by Zacks Equity Research
Robust sales contribution across operating segments drove Illumina's (ILMN) Q2 top line.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
bluebird bio (BLUE) Focused on Pipeline Amid Marketed Drug Dearth
by Zacks Equity Research
bluebird bio's (BLUE) efforts to develop its gene-therapy pipeline are impressive. The FDA is reviewing BLUE's filing for beti-cel as a treatment for beta thalassemia and eli-cel for cerebral adrenoleukodystrophy.
National Vision (EYE) Q2 Earnings Top Mark, Revenue View Cut
by Zacks Equity Research
National Vision (EYE) is simultaneously facing demand headwinds across its network of stores, given the current macro environment, as well as supply challenges.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
ResMed (RMD) Q4 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
ResMed (RMD) posts better-than-expected Q4 results with continued strength in sleep and respiratory care devices sales performance.
J&J (JNJ) to Stop Selling Talc-based Baby Powder From 2023
by Zacks Equity Research
J&J (JNJ) will stop selling its talcum-based baby powder globally from next year. Though reports claim that the use of the talc causes cancer, JNJ maintains its stance that this product is safe.
STERIS (STE) Gains From Cantel Buyout, Supply Chain Issue Stays
by Zacks Equity Research
Revenue growth at STERIS' (STE) Applied Sterilization Technologies is driven by increased demand from medical device and biopharma customers.
Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Haemonetics (HAE) posts better-than-expected results in Q1 with robust contributions from the Hospital business.
Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe
by Zacks Equity Research
Seagen (SGEN) focuses on improving sales of its marketed drugs approved for different types of cancer indications. Stiff competition in the market remains a woe.
Omnicell (OMCL) Q2 Earnings Miss Estimates, Gross Margin Down
by Zacks Equity Research
Robust sales contribution from product and services segments drove Omnicell's (OMCL) Q2 top line.
Exelixis (EXEL) Q2 Earnings Beat, Cabometyx Maintains Growth
by Zacks Equity Research
Exelixis (EXEL) tops earnings and sales in the second quarter as lead drug Cabometyx maintains momentum.
SmileDirectClub (SDC) Q2 Earnings Lag Estimates, Guidance Cut
by Zacks Equity Research
SmileDirectClub (SDC) witnesses a drop in both net and financing revenues on a year-over-year basis.
Q2 Earnings Scorecard and Analyst Reports for Roche, Adobe & McDonald's
by Sheraz Mian
Today's Research Daily features update on the Q2 earnings season and new research reports on Roche (RHHBY), Adobe (ADBE), and McDonald's (MCD).
Insulet (PODD) Q2 Earnings Miss Estimates, '22 Sales View Up
by Zacks Equity Research
Insulet (PODD) posts better-than-expected revenues in Q2 with robust contributions from Total Omnipod.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Analyst Blog Highlights Exxon Mobil, Merck & Co, Chevron, American Electric Power and The Southern
by Santanu Roy
Exxon Mobil, Merck & Co, Chevron, American Electric Power and The Southern are part of Zacks Analyst Blog.
NuVasive (NUVA) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
NuVasive's (NUVA) Q2 revenues outpaced the consensus mark with strong sales across U.S. Spinal Hardware and Surgical Support businesses.
5 High-Flying U.S. Corporate Giants to Buy Despite Volatility
by Nalak Das
We have narrowed our search to five U.S. corporate giants. These are; XOM, CVX, AEP, MRK and SO.